Widely used:Recently Viewed
Clear All
$13 Mln
--
1.47
--
0.01
-42.92 %
-42.44 %
--
--
--
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Immuron - ADR (IMRN)
| 18.39 | -17.48 | -2.64 | 18.08 | -15.66 | -6.34 | -- |
|
BSE Sensex*
| 13.24 | -1.31 | 1.60 | 23.42 | 10.09 | 16.44 | 12.00 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Immuron - ADR (IMRN)
| -9.86 | -16.80 | -60.75 | 75.48 | -37.17 | 9.64 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$12.53 Mln
$--
$--
$0.00 Mln
$--
Low
$1.48 - 5.96
5,694,960
NASDAQ: IMRN
Carlton, VIC
https://www.immuron.com.au
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments,... Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia. Address: 62 Lygon Street, Carlton, VIC, Australia, 3053 Read more
The total asset value of Immuron Limited - ADR (IMRN) stood at $ 16 Mln as on 30-Jun-24
The share price of Immuron Limited - ADR (IMRN) is $2.22 (NASDAQ) as of 14-Oct-2024 16:00 EDT. Immuron Limited - ADR (IMRN) has given a return of -15.66% in the last 3 years.
Immuron Limited - ADR (IMRN) has a market capitalisation of $ 13 Mln as on 14-Oct-2024. As per Value Research classification, it is a company.
Since, TTM earnings of Immuron Limited - ADR (IMRN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Immuron Limited - ADR (IMRN) and enter the required number of quantities and click on buy to purchase the shares of Immuron Limited - ADR (IMRN).
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia. Address: 62 Lygon Street, Carlton, VIC, Australia, 3053
The CEO & director of Mr. Steven George Lydeamore CPA, M.B.A.. is Immuron Limited - ADR (IMRN), and CFO & Sr. VP is Mr. Steven George Lydeamore CPA, M.B.A..
There is no promoter pledging in Immuron Limited - ADR (IMRN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
110
|
|
|
90
|
|
|
59
|
|
|
45
|
| Immuron Limited - ADR (IMRN) | Ratios |
|---|---|
|
Return on equity(%)
|
-42.92
|
|
Operating margin(%)
|
-129.4
|
|
Net Margin(%)
|
-141.49
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Immuron Limited - ADR (IMRN) was No Profit.
$0.02
